Ondine Biomedical shares Ottawa Hospital study on Steriwave nasal photodisinfection helping patients

Ondine Biomedical Vice President for Clinical and Medical Affairs Jason Hickok joins Proactive's Natalie Stoberman to share the results of its 2022 quality improvement study for Steriwave nasal photodisinfection.

Hickok says the study shows spine surgery patients treated with Ondine Biomedical’s Steriwave nasal photodisinfection on average had a 48% shorter length of hospital stay compared with those not treated.

The study also shows there was a 33% reduction in the rate of return to the emergency department, as well as a 51% reduction in the rate of readmissions.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com